# University of Nebraska at Omaha

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/university-of-nebraska-at-omaha/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 62.5 |
| Citations | 757,930 |
| City | Omaha |
| Country | US |
| Description | University of Nebraska at Omaha is a research organisation in Omaha, US. OpenAlex records 22,737 works and 757,930 citations for it. 4,010 researchers list it as their most recent affiliation. |
| Homepage | https://www.unomaha.edu |
| OpenAlex ID | https://openalex.org/I122266389 |
| Region | Nebraska |
| Researchers | 4,010 |
| ROR ID | https://ror.org/04yrkc140 |
| Type | education |
| Works | 22,737 |

## University papers

Showing 12 of 23.

- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial](https://scholariq.org/papers/niraparib-monotherapy-for-late-line-treatment-of-ovarian-cancer-quadra-a/)
- [Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial](https://scholariq.org/papers/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients/)
- [Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer](https://scholariq.org/papers/mirvetuximab-soravtansine-in-fr-positive-platinum-resistant-ovarian-cancer/)
- [Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of/)
- [Levodopa <scp>I</scp>s a <scp>D</scp>ouble‐<scp>E</scp>dged <scp>S</scp>word for <scp>B</scp>alance and <scp>G</scp>ait in <scp>P</scp>eople <scp>W</scp>ith <scp>P</scp>arkinson's <scp>D</scp>isease](https://scholariq.org/papers/levodopa-scp-i-scp-s-a-scp-d-scp-ouble-scp-e-scp-dged-scp-s-scp-word-for-scp-b/)
- [A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)](https://scholariq.org/papers/a-randomized-phase-iii-trial-to-evaluate-rucaparib-monotherapy-as-maintenance/)
- [The forefront of ovarian cancer therapy: update on PARP inhibitors](https://scholariq.org/papers/the-forefront-of-ovarian-cancer-therapy-update-on-parp-inhibitors/)
- [Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-2/)
- [Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial](https://scholariq.org/papers/durvalumab-plus-carboplatin-paclitaxel-followed-by-maintenance-durvalumab-with/)
- [Validity of Mobility Lab (version 2) for gait assessment in young adults, older adults and Parkinson’s disease](https://scholariq.org/papers/validity-of-mobility-lab-version-2-for-gait-assessment-in-young-adults-older/)

## University researchers

- [Carolin Curtze](https://scholariq.org/researchers/carolin-curtze/)

## University top topics

Showing 8 of 24.

- [Crime Patterns and Interventions](https://scholariq.org/topics/crime-patterns-and-interventions/)
- [Balance, Gait, and Falls Prevention](https://scholariq.org/topics/balance-gait-and-falls-prevention/)
- [Criminal Justice and Corrections Analysis](https://scholariq.org/topics/criminal-justice-and-corrections-analysis/)
- [Team Dynamics and Performance](https://scholariq.org/topics/team-dynamics-and-performance/)
- [Monetary Policy and Economic Impact](https://scholariq.org/topics/monetary-policy-and-economic-impact/)
- [Market Dynamics and Volatility](https://scholariq.org/topics/market-dynamics-and-volatility/)
- [Child and Adolescent Psychosocial and Emotional Development](https://scholariq.org/topics/child-and-adolescent-psychosocial-and-emotional-development/)
- [Knowledge Management and Sharing](https://scholariq.org/topics/knowledge-management-and-sharing/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.